Capstone Therapeutics Corp. (NASDAQ:CAPS) Stock Short Interest Falls 65.6%

Capstone Therapeutics Corp. (NASDAQ:CAPS) saw a significant decrease in short interest in the month of October. As of October 15th, there was short interest totaling 696,378 shares, a decrease of 65.6% from the September 30th total of 2,025,068 shares. Currently, 130.4% of the company’s stock are short sold. Based on an average daily trading volume, of 1,178,085 shares, the short-interest ratio is currently 0.6 days.

Capstone Therapeutics Stock Down 3.5%

Capstone Therapeutics stock traded down $0.10 during midday trading on Thursday, reaching $2.73. The company’s stock had a trading volume of 8,468 shares, compared to its average volume of 92,320. The stock’s 50-day simple moving average is $4.58 and its 200-day simple moving average is $11.17. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.99 and a quick ratio of 0.39. Capstone Therapeutics has a 52-week low of $2.33 and a 52-week high of $34.80. The stock has a market capitalization of $2.40 million, a P/E ratio of -0.03 and a beta of -1.50.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings upgraded shares of Capstone Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, October 23rd. One equities research analyst has rated the stock with a Sell rating. According to MarketBeat, the stock has a consensus rating of “Sell”.

Capstone Therapeutics Company Profile

Capstone Therapeutics Corporation was a biotechnology company focused on developing peptide-based therapeutics for tissue repair and regenerative medicine. Its research programs centered on synthetic peptides designed to influence healing and recovery in areas such as bone, soft tissue and cardiovascular injury.

The company’s principal historical programs included Chrysalin (TP508), an experimental peptide derived from a portion of the human thrombin protein that was investigated for applications in bone and tissue healing, and AZX100, a peptide-based candidate studied for its potential to reduce fibrosis and postsurgical scarring.